208 related articles for article (PubMed ID: 22404917)
21. Role of late sodium channel current block in the management of atrial fibrillation.
Burashnikov A; Antzelevitch C
Cardiovasc Drugs Ther; 2013 Feb; 27(1):79-89. PubMed ID: 23108433
[TBL] [Abstract][Full Text] [Related]
22. Atrial-selective drugs for treatment of atrial fibrillation.
Ravens U; Christ T
Herzschrittmacherther Elektrophysiol; 2010 Dec; 21(4):217-21. PubMed ID: 21082185
[TBL] [Abstract][Full Text] [Related]
23. Antiarrhythmic and cardiac electrophysiological effects of SZV-270, a novel compound with combined Class I/B and Class III effects, in rabbits and dogs.
Varga RS; Hornyik T; Husti Z; Kohajda Z; Krajsovszky G; Nagy N; Jost N; Virág L; Tálosi L; Mátyus P; Varró A; Baczkó I
Can J Physiol Pharmacol; 2021 Jan; 99(1):89-101. PubMed ID: 32970956
[TBL] [Abstract][Full Text] [Related]
24. Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation.
Burashnikov A; Petroski A; Hu D; Barajas-Martinez H; Antzelevitch C
Heart Rhythm; 2012 Jan; 9(1):125-31. PubMed ID: 21884675
[TBL] [Abstract][Full Text] [Related]
25. Atrial selectivity of antiarrhythmic drugs.
Ravens U; Poulet C; Wettwer E; Knaut M
J Physiol; 2013 Sep; 591(17):4087-97. PubMed ID: 23732646
[TBL] [Abstract][Full Text] [Related]
26. Atrial-ventricular differences in rabbit cardiac voltage-gated Na
Caves RE; Cheng H; Choisy SC; Gadeberg HC; Bryant SM; Hancox JC; James AF
Heart Rhythm; 2017 Nov; 14(11):1657-1664. PubMed ID: 28610990
[TBL] [Abstract][Full Text] [Related]
27. Maastricht antiarrhythmic drug evaluator (MANTA): A computational tool for better understanding of antiarrhythmic drugs.
Sutanto H; Laudy L; Clerx M; Dobrev D; Crijns HJGM; Heijman J
Pharmacol Res; 2019 Oct; 148():104444. PubMed ID: 31493513
[TBL] [Abstract][Full Text] [Related]
28. Tetrodotoxin-Sensitive Neuronal-Type Na
Munger MA; Olğar Y; Koleske ML; Struckman HL; Mandrioli J; Lou Q; Bonila I; Kim K; Ramos Mondragon R; Priori SG; Volpe P; Valdivia HH; Biskupiak J; Carnes CA; Veeraraghavan R; Györke S; Radwański PB
J Am Heart Assoc; 2020 Jun; 9(11):e015119. PubMed ID: 32468902
[TBL] [Abstract][Full Text] [Related]
29. Atrial antifibrillatory effects of structurally distinct IKur blockers 3-[(dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in dogs with underlying heart failure.
Regan CP; Kiss L; Stump GL; McIntyre CJ; Beshore DC; Liverton NJ; Dinsmore CJ; Lynch JJ
J Pharmacol Exp Ther; 2008 Jan; 324(1):322-30. PubMed ID: 17967939
[TBL] [Abstract][Full Text] [Related]
30. An N-/L-type calcium channel blocker, cilnidipine, suppresses autonomic, electrical, and structural remodelling associated with atrial fibrillation.
Tajiri K; Guichard JB; Qi X; Xiong F; Naud P; Tardif JC; Costa AD; Aonuma K; Nattel S
Cardiovasc Res; 2019 Dec; 115(14):1975-1985. PubMed ID: 31119260
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the effects of I
Juhász V; Hornyik T; Benák A; Nagy N; Husti Z; Pap R; Sághy L; Virág L; Varró A; Baczkó I
Can J Physiol Pharmacol; 2018 Jan; 96(1):18-25. PubMed ID: 28892643
[TBL] [Abstract][Full Text] [Related]
32. Antiarrhythmic drug therapy for atrial fibrillation: focus on atrial selectivity and safety.
Li D; Sun H; Levesque P
Cardiovasc Hematol Agents Med Chem; 2009 Jan; 7(1):64-75. PubMed ID: 19149545
[TBL] [Abstract][Full Text] [Related]
33. The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation.
Wettwer E; Christ T; Endig S; Rozmaritsa N; Matschke K; Lynch JJ; Pourrier M; Gibson JK; Fedida D; Knaut M; Ravens U
Cardiovasc Res; 2013 Apr; 98(1):145-54. PubMed ID: 23341576
[TBL] [Abstract][Full Text] [Related]
34. Atria-selective antiarrhythmic drugs in need of alliance partners.
Peyronnet R; Ravens U
Pharmacol Res; 2019 Jul; 145():104262. PubMed ID: 31059791
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.
Tsuji Y; Dobrev D
Vasc Health Risk Manag; 2013; 9():165-75. PubMed ID: 23637539
[TBL] [Abstract][Full Text] [Related]
36. Widening of the excitable gap and enlargement of the core of reentry during atrial fibrillation with a pure sodium channel blocker in canine atria.
Kawase A; Ikeda T; Nakazawa K; Ashihara T; Namba T; Kubota T; Sugi K; Hirai H
Circulation; 2003 Feb; 107(6):905-10. PubMed ID: 12591763
[TBL] [Abstract][Full Text] [Related]
37. Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility.
Singh BN
J Cardiovasc Electrophysiol; 1999 Feb; 10(2):283-301. PubMed ID: 10090235
[TBL] [Abstract][Full Text] [Related]
38. Investigational Anti-Atrial Fibrillation Pharmacology and Mechanisms by Which Antiarrhythmics Terminate the Arrhythmia: Where Are We in 2020?
Burashnikov A
J Cardiovasc Pharmacol; 2020 Nov; 76(5):492-505. PubMed ID: 33165131
[TBL] [Abstract][Full Text] [Related]
39. Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide.
Wang J; Feng J; Nattel S
Circulation; 1994 Oct; 90(4):2032-40. PubMed ID: 7923691
[TBL] [Abstract][Full Text] [Related]
40. Can inhibition of IKur promote atrial fibrillation?
Burashnikov A; Antzelevitch C
Heart Rhythm; 2008 Sep; 5(9):1304-9. PubMed ID: 18774108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
